A high tumor mutational burden (TMB) (Yarchoan et al. 2017) and strong expression of programmed death ligand 1 (PD-L1) (Topalian et al. 2012) were shown to be broadly associated with response to immunotherapy in several cancer types and were suggested as tumor-agnostic biomarkers. The gene discussed is CD274; the disease is neoplasm.